ONO 1301

Subscribe to Selected New Research on ONO 1301

4 relevant articles (1 outcomes, 0 trials/studies) found for this Bio-Agent

Description: a non-prostanoid prostaglandin I2 mimetic coumpound with inhibitory activity against thromboxane A2 synthase; structure given in first source

Also Known As:

(7,8-dihydro-5-((E)-((a-(3-pyridyl)benzylidene)aminooxy)ethyl)-1-naphthyloxy)acetic acid; ONO-1301

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Pyridines: 26

ONO 1301: 4

Related Diseases

1.	Pulmonary Hypertension (Ayerza Syndrome) 12/15/2005 - "METHODS: After subcutaneous injection of monocrotaline or vehicle, rats were randomized to receive repeated subcutaneous administration of ONO-1301 or vehicle twice per day for 3 wk. MEASUREMENTS AND MAIN RESULTS: There was significant development of pulmonary hypertension 3 wk after monocrotaline injection" 12/15/2005 - "OBJECTIVES: We investigated whether modulation of prostacyclin/thromboxane balance by ONO-1301 ameliorates monocrotaline-induced pulmonary hypertension in rats" Get all the results and reference details, order at left...
2.	Pulmonary Fibrosis (Hamman Rich Syndrome) 01/01/2006 - "Thus we investigated whether repeated administration of ONO-1301 attenuates bleomycin-induced pulmonary fibrosis in mice" 01/01/2006 - "These results suggest that repeated administration of ONO-1301 attenuates the development of bleomycin-induced pulmonary fibrosis and improves survival in bleomycin mice, at least in part by inhibition of TXA2 synthesis and activation of the cAMP/PKA pathway." 01/01/2006 - "ONO-1301 significantly attenuated the development of bleomycin-induced pulmonary fibrosis, as indicated by significant decreases in Ashcroft score and lung hydroxyproline content" Get all the results and reference details, order at left...
3.	Nephritis 01/01/1997 - "ONO-1301 was orally given to crescentic-type anti-GBM nephritic rats for 40 days after the induction of nephritis" 01/01/1997 - "The antinephritic effects of ONO-1301 ([7,8-dihydro-5-[(E)-[[a-(3-pyridyl)benzylidene]-aminooxy]ethyl]-1 -naphtyloxy]acetic acid) on crescentic-type anti-glomerular basement membrane (GBM) nephritis in rats were investigated" 01/01/1997 - "Modulation of anti-glomerular basement membrane nephritis in rats by ONO-1301, a non-prostanoid prostaglandin I2 mimetic compound with inhibitory activity against thromboxane A2 synthase." Get all the results and reference details, order at left...
4.	Flushing 12/01/1997 - "Each six dogs were comprised I2-10 and I2-50 groups respectively, with receiving a 10-minute infusion of ONO-1301 (10 micrograms/kg/min) before flushing" Get all the results and reference details, order at left...
5.	Edema 12/01/1997 - "Although it dose not protect the implanted lung completely from developing edema, the ONO-1301 administration (10 micrograms/kg/min) to the donor and the recipient resulted in prevention of TXA2 and PGI2 release and improvement of the respiratory function and pulmonary hemodynamics after reperfusion" Get all the results and reference details, order at left...
7 Diseases and 4 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Epoprostenol (Prostacyclin)
2.	Monocrotaline
3.	Acetic Acid (Vinegar)
4.	Thromboxane A2 (A2, Thromboxane)
5.	Hydroxyproline (4 Hydroxyproline)
6.	Bleomycin (Blenoxane)
7.	antiglomerular basement membrane antibody
8.	indium-bleomycin
8 Drugs and Important Bio-Agents and 4 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>